Posted in M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic April 8, 2026 Pharmaceutical Technology The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic. M&A / DealsOncologyRead full story